Alaunos Therapeutics 2 articles

Alaunos Therapeutics is a biopharmaceutical company whose scientific profile centers on metabolic disease. Its work connects ALN1003 oral small molecule with non-hormonal obesity therapeutics, placing the company in a specific mechanistic and therapeutic niche rather than a broad life-science category. The pairing of body weight and fat mass biology and insulin sensitivity modulation adds a second layer of entity context for Alaunos Therapeutics.

Biotechnology News & Analysis

October 14, 2026, 8:48 AM · 3 mins read

Liquidia jumps 41% after settlement as CDT slides

Liquidia rose 41% in Wednesday pre-market trading after settling litigation with United Therapeutics. CDT Equity fell 45%, while Alaunos advanced after completing its Velaris acquisition and raising $350 million.

AI in Biology

October 14, 2026, 7:27 AM · 5 mins read

Alaunos closes Velaris deal as biotech peers post updates

Alaunos has completed its acquisition of Velaris, adding a portfolio of cardiopulmonary biologics. Four other companies reported advances in Alzheimer’s AI and cancer research, alongside updates on protein production and predictive toxicology.